Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The fun will really begin when we get those couple hundred million volume days back. Then we know we might be out of that channel we’ve been in.
We might actually see 40+ million in volume today. That would be a start in the right direction.
Volume is there but I won’t get excited until we are sitting/holding at around 15 cents. That’s our near future sweet spot for now.
Let’s hope it holds. Days like this are bringing back some fun memories.
I agree. Many more good things to come.
I apologize! After reading what you just said to me it opened my eyes and I realized what I was doing. I’m having a rough couple weeks with health issues and I guess me rambling in Discord and in IHUB was my way of venting for a few. Promise it won’t happen again. Thanks for calling me out I needed that.
Thanks for the response.
Yea Enzolytics not being able to or not wanting to tell us is a very good possibility and most likely the case. Ultimately, only time will tell. I’ve always believed in this company and I’m thankful for the SAGA shares that will soon come our way. I’m sure the leadership has been extremely busy trying to get this deal closed.
Thanks can’t wait for all the info to come rolling out.
I have plenty of patience with Enzolytics and I wasn’t asking repetitive questions at all. I was replying to other members in the discord at the time. Explaining what I meant by my post to multiple people replying to me is not me asking repetitive questions it’s me talking to multiple people simultaneously. How else was I supposed to respond to everyone asking me things?
What I roughly said this morning was I wish that Enzolytics would PR something so us shareholders know what road they plan on going down and we can better understand the future of ENZC after the deal is done.
I was basically told just believe in the team and leadership. Which I do but when my money is invested in a company I don’t think it’s a lot to ask that ENZC tells us their future plans. It worries me a little that the PR stated ENZC will have to implement a new business strategy being they won’t have any assets after this deal is signed.
I appreciate the honesty. I agree it wasn’t right. I didn’t say anything bad about ENZC or SAGA. In fact I was asked to drop it and I did but was then baited by someone who wanted to keep coming at me.
Yes some unrealistic views but I definitely enjoyed the Discord. It’s a shame you can get booted for just having your own opinion / thoughts and I wasn’t even bashing the company. People raised their own concerns in there often and that’s all I was doing.
I guess I’ll be hanging around here from now on cause I was banned from the Discord earlier. I won’t mention any names no hard feelings. I genuinely enjoyed the discord but I guess when you mention certain things and someone doesn’t agree with it you get the boot. I’ve been a shareholder longer than 99% of them in there and wrote minor valid concerns i had but I guess that’s unacceptable. I know some people will see this that belong to discord so I just wanted to wish you all the best. I enjoyed reading everyone’s opinions on a daily basis. Hopefully one day I’ll be allowed back in.
Both haha
Using easy numbers to explain…
100 million outstanding common SAGA shares
Let’s just assume a 2.5 billion dollar evaluation for SAGA.
This makes SAGA worth $25/share
Let’s assume a conversion rate for every 1 million shares of ENZC you own you will get approx 35,000 SAGA shares.
So with this said you don’t believe that BGEN & VIRO / SAGA could be worth 10 times that amount giving us a 25 billion dollar evaluation or $250 per share once they successfully complete animal studies etc.?
Might be wishful thinking on my part but I certainly don’t think it is far fetched.
This really all comes down to the share structure of SAGA which we will soon find out the details. The same gains can absolutely be made with SAGA shares that we thought we would get with ENZC shares.
It’s possible that 900million shares could be going to SAGA shareholders when ENZC buys out/merges with SAGA (our quick way into the nasdaq).
It’s not so far fetched of an idea.
This SPAC company could be our way into Nasdaq. Very good possibility that’s what is happening here.
What are everyone’s thoughts on the golden cross taking place on the day before filings must be submitted? Very interesting timing for it to take place.
Absolutely agree!!!
Sort of. I wouldn’t necessarily say working out the wrinkles. This inventory issue was strictly due to being a brand new item listed and shipped to Amazon fulfillment centers. Those 15 or so bottles that first showed up on amazon and were sold out were just the first few bottles that were received and scanned at a specific amazon warehouse and once scanned they became available on the Enzolytics IPF listing. On a little side note one of two things happened, IPF immune sold out the small inventory that was first available (give or take 15 bottles) or Enzolytics turned the listing off and made it unavailable. The reason Enzolytics would do this is to wait for the full inventory to show its available and stocked then make the listing go live again. When you sell on Amazon and you sign into your sellers account it will show you for example 15 out of 5,000 bottles were received and made available to sell. It is very possible that they simply made it unavailable and are waiting a few days to a week or so until they get notified all the inventory is stocked and ready to ship from Amazon fulfillment centers.
Posted this on discord but I figured I’d add it here also for clarification on why Enzolytics launched their IPF Immune with only a small amount of inventory…..
Just an FYI the reason for limited quantities for ipf immune on Amazon is because when you ship for example 500 bottles of ipf it gets distributed throughout the country to different warehouses. 10 bottles might get shipped to one warehouse 100 bottles maybe to another etc. I can almost guarantee they shipped a decent amount to Amazon fulfillment centers but when your product you list first goes live on Amazon you see this exact scenario happen with quantities. In the next couple days to a week you will see it become completely stocked.
What a crazy day today has been for us
Sorry haven’t seen or heard that one but I will try and find it.
Can you provide a link to that? I would like to hear regen say that. I’m not doubting you I just want to hear it for myself.
Thinking the same thing. Not only did we have a little spike in volume but it was allowed to move. Which is very interesting!!
Here he goes again talking nonsense and spitting lies about Enzolytics. No proof to back anything you just said. Trying your best to spread fear. Goodluck with your agenda
1. Big companies like Lonza dot their i’s and cross their T’s. Nothing wrong with waiting a little longer. What’s the rush?
2. I guess you need to go back and do some DD and pay attention to the the interviews with hicks when the intel collaboration was brought up and said they are working out the details.
“The consortium” between Enzolytics, Intel & the ministry of health Estonia.
3. Audited filings take time! There’s been no issues brought up by MaloneBailey. That came from CEO himself.
4. Montana results will be released.
I will ask again. What’s the rush?
$ENZC - Yes, there was a delay in a "Joint PR next week". Per Lonza's response, there is a working relationship between the two and they are fixing the inaccuracies. They are obviously not going to pre-announce a joint PR
— 𝐆𝐨𝐝𝐟𝐚𝐭𝐡𝐞𝐫 𝐂𝐚𝐩𝐢𝐭𝐚𝐥 (@GodfatherCap) July 30, 2021
Still a major win for the company.
Onwards & Upwards pic.twitter.com/bXCSfYuLgE
There’s a pic of an email from Lonza. It’s from the investor relations officer Dirk Oehlers. He confirms in the email that Lonza is working with Enzolytics. Have you checked that out?
There were no lies! Stop spreading false information about the company.
If you are referring to Lonza they confirmed they are working with Enzolytics. Obviously details are being worked out and the joint PR will come when they are done.
Last time I checked Friday (tomorrow) is a trading day. Chandra said next week. Your statement would be true about Chandra lying on hicks show after tomorrow ends without a PR until then stop spreading your own lies about ENZC just so you can pick up shares cheaper. We know that’s your agenda.
Yes but please you must look at market cap when looking at these price jumps. SAVA market cap is a little more than 4 billion. When ENZC market cap hits equivalent 4 billion ENZC share price will jump to approx $1.50. All I’m saying is don’t just look at share prices of different company’s.
Explanation behind that ridiculous statement about them getting an SEC suspension?
Oh wait I know why cause you’re still trying your hardest to get those .16’s you wanting and never got 2 weeks ago. Give it a rest already with the crazy statements about ENZC.
Just in case someone would rather the link here it is…..
https://finance.yahoo.com/news/enzolytics-reports-progress-toward-completion-113000008.html
Enzolytics Reports Its Progress Toward Completion Of Clinical Trials for Its ITV-1 ANTI-HIV Therapeutic and Securing Use Authorization Under the European Medicines Agency
Thursday, July 29, 2021 7:30 AM
COLLEGE STATION, TX / ACCESSWIRE / July 29, 2021 / Enzolytics, Inc. (OTC PINK:ENZC) (http://enzolytics.com/) has completed arrangements and agreements with Danhson (https://danhson.bg/en/) and Clinic Design (https://clinicdesign.eu/) to advance its anti-HIV therapeutic ITV-1 to production and clinical trials. These steps are prefatory to approval by the European Medicines Agency (EMA), leading to patient use authorization.
Production of the therapeutic will be accomplished at Danhson pharmaceutical company facilities, to be followed by clinical trials conducted by Clinic Design. Production of the therapeutics is expected to be completed in the next few months followed by clinical trials to be conducted immediately thereafter. The protocol of the trials will be guided by Pharmalex (https://www.pharmalex.com/), an EU regulatory consulting company.
Earlier in the year, the Company announced the formation of International Medical Partners ("IMPL"), a Bulgarian Limited Liability Company, of which the Company is 50% owner. Pursuant to that formation, the Company will fund the initial production of the ITV-1 therapeutic and the Company's partners in IMBL will fund the cost of the clinical trials and cost of EMA permitting.
IMBL will be the exclusive distributor of the ITV-1 therapeutic in the European Medicines Agency member countries (namely all 27 European Union member states and Iceland, Liechtenstein and Norway) as well as the countries of Russia, Georgia, Ukraine, Moldova, Belarus, Armenia, Azerbaijan, Kazakhstan, Uzbekistan, Turkmenistan, Kyrgyzstan, Tajikistan, Estonia, Latvia and Lithuania. IMBL may distribute the ITV-1 therapeutic outside of its exclusive territory where an exclusive license does not otherwise exist.
All documentation for registration of IMPL has been filed with the Registry Office in Sofia. The initial funding of IMBL, by Enzolytics and its partners, has been provided by the partners.
The Company's two-year audit is proceeding in accordance with GAAP requirements and will be completed and filed as soon as completed. The audit is proceeding as planned without any unanswered issues.
Harry Zhabilov, CSO of Enzolytics, stated, "We are excited about the progress we have made with the assistance of our IMBL partners. Contracting with Danhson, Clinic Design and PharmaLex is integral to the success of the EMA permitting process. As this is the second time our ITV-1 therapeutic has progressed through clinical trials and the first trials were successful, we are fully confident that we will succeed in the permitting process. With the reciprocal treaty between the EMA and FDA, we believe that the EMA approval with lead to further advancement of our ITV-1 as a successful therapy."
About Enzolytics, Inc.
Enzolytics, Inc. is a drug development company committed to the commercialization of its proprietary proteins and monoclonal antibodies for the treatment of debilitating infectious diseases. The Company is advancing multiple therapeutics targeting numerous infectious diseases. One patented and clinically tested compound, ITV-1 (Immune Therapeutic Vaccine-1), is a suspension of Inactivated Pepsin Fraction (IPF), which studies have shown is effective in treating HIV/AIDS. IPF is the active component of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has also been shown to modulate the immune system.
The Company is also implementing its proprietary technology to produce fully human monoclonal antibodies (mAbs) against infectious diseases, including HIV, rabies, influenza A, influenza B, tetanus, and diphtheria. Its proprietary methodology for producing fully human monoclonal antibodies is currently being employed to produce monoclonal antibody therapeutics for numerous infectious diseases, including the Coronavirus (SARS-CoV-2) and HTLV-1.
Forward Looking Statements
This news release may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of our company, are generally identified by use of words "anticipate," "believe," "estimate," "expect," "intend," "plan," "project," "seek," "strive," "try," or future or conditional verbs such as "could," "may," "should," "will," "would," or similar expressions. Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain. Accordingly, actual results may differ materially from anticipated results. Some of the factors that could cause our actual results to differ from our expectations or beliefs include, without limitation, the risks discussed from time to time in our filings with the Securities and Exchange Commission or OTC Markets. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Certain forward-looking statements may involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Enzolytics, Inc. from time to time in its periodic reports filed with the SEC. ITV-1 is not approved by the U.S. Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world.
While Enzolytics, Inc. believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of the Company to establish the efficacy of ITV-1 or its other therapeutics in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of its therapeutics in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate.
Such forward-looking statements are based on current expectations. They involve inherent risks and uncertainties, including factors that could delay, divert or change any of the statements made, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. These forward-looking statements are made as of the date of this press release. The Company expressly disclaims any intention or obligation to update the forward-looking statements or update the reasons why actual results could differ from those projected in the forward-looking statements.
I.R. contact
TEN Associates, LLC
Tom Nelson, CEO
(480) 326-8577
Investor Relations Contact
Company Contact
Enzolytics, Inc.
2000 North Central Expressway
Plano, TX 75074
and
Research Center
Enzolytics, Inc.
Texas A&M University
Institute for Preclinical Studies
College Station, TX 77843
SOURCE: Enzolytics, Inc.
Still waiting for the .16 call you were making a couple weeks ago??
Buy more so you can average down and maybe you’ll be happy again.
This is my opinion. Why else would the PR be removed. If ENZOLYTICS issues a PR and suddenly it is deleted/removed what other logical explanation would it be other than Lonza said remove it. Maybe I’m wrong but with Chandra saying joint PR this week I’m betting Lonza said to remove it.